Safety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthma

Hdl Handle:
http://hdl.handle.net/10147/597035
Title:
Safety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthma
Authors:
Sahadevan, A; Cusack, R; Lane, SJ
Journal:
Irish Medical Journal
Issue Date:
Dec-2015
URI:
http://hdl.handle.net/10147/597035
Abstract:
Seasonal allergic rhinitis (AR) occurs predominantly as a result of grass pollen allergy. Grass pollen sublingual immunotherapy (SLIT) has been proven effective in treating AR 1 . SLIT is currently licensed for use in AR with concomitant stable mild asthma. There is evidence that SLIT improves asthma control when primarily used to treat AR 2 . The aim was to assess the safety of SLIT in patients with severe seasonal allergic rhinitis who have co-existing stable mild asthma. The secondary aim was to determine whether asthma control improved post SLIT. There was no deterioration in asthma control after 6-36 months of SLIT. 27/30 (90%) patientsâ asthma control remained stable or indeed improved (p<0.021). Of this 15 (50%) patientsâ asthma improved. There was no statistically significant change in their asthma pharmacotherapy after SLIT (p=0.059). In conclusion, grass pollen SLIT is safe and can potentially treat dual allergic rhinitis- mild asthmatic patients.
Item Type:
Article
Language:
en
Keywords:
RHINITIS; HAY FEVER; ASTHMA

Full metadata record

DC FieldValue Language
dc.contributor.authorSahadevan, Aen
dc.contributor.authorCusack, Ren
dc.contributor.authorLane, SJen
dc.date.accessioned2016-02-23T15:10:38Zen
dc.date.available2016-02-23T15:10:38Zen
dc.date.issued2015-12en
dc.identifier.urihttp://hdl.handle.net/10147/597035en
dc.description.abstractSeasonal allergic rhinitis (AR) occurs predominantly as a result of grass pollen allergy. Grass pollen sublingual immunotherapy (SLIT) has been proven effective in treating AR 1 . SLIT is currently licensed for use in AR with concomitant stable mild asthma. There is evidence that SLIT improves asthma control when primarily used to treat AR 2 . The aim was to assess the safety of SLIT in patients with severe seasonal allergic rhinitis who have co-existing stable mild asthma. The secondary aim was to determine whether asthma control improved post SLIT. There was no deterioration in asthma control after 6-36 months of SLIT. 27/30 (90%) patientsâ asthma control remained stable or indeed improved (p<0.021). Of this 15 (50%) patientsâ asthma improved. There was no statistically significant change in their asthma pharmacotherapy after SLIT (p=0.059). In conclusion, grass pollen SLIT is safe and can potentially treat dual allergic rhinitis- mild asthmatic patients.en
dc.language.isoenen
dc.subjectRHINITISen
dc.subjectHAY FEVERen
dc.subjectASTHMAen
dc.titleSafety of grass pollen sublingual immunotherapy for allergic rhinitis in concomitant asthmaen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.